• Tuberculosis and Respiratory Diseases
• /
• 제53권6호
• /
• pp.656-661
• /
• 2002

저자들은 불응성 상심실성 빈맥으로 저용량 amiodarone을 장기간 사용한 환자에서 발생한 폐독성을 경험하고 적절히 치료하였기에 이를 보고하는 바이다.

• Tuberculosis and Respiratory Diseases
• /
• 제59권4호
• /
• pp.413-417
• /
• 2005

Amiodarone을 사용하는 환자에서 객혈이 발생하였을 경우 원인으로 amiodarone의 폐독성을 반드시 고려하여야 하며 즉시 투여를 중지하고 스테로이드를 사용하면 임상 증상을 호전시킬 수 있다. 저자들은 저용량의 amiodarone을 장기간 사용하던 환자에서 발생한 객혈을 약물 투여 중지 및 대증적 치료로 호전시킨 1예를 경험하여 문헌 고찰과 함께 보고하는 바이다.

• 식품보건융합연구
• /
• 제5권4호
• /
• pp.13-17
• /
• 2019

Amiodarone hydrochloride is an antiarrhythmic agent which has low aqueous solubility and presents bioavailability problem. These properties are a challenge for the pharmaceutical industry. Inclusion of lipophilic compound in the hydrophobic core of micelles, i.e. self-assembled structures based on surfactants in aqueous solution, is one way of increasing the solubility. Intravenous formulation of amiodarone hydrochloride with polysorbate 80 as a detergent and benzyl alcohol as a co-solvent is used in medical practice. This paper aimed to study the effect of polysorbate 80 and benzyl alcohol on the water solubility of amiodarone hydrochloride. Formation of mixed micelles consisting of nonionic surfactant polysorbate 80 and cationic amiodarone with chloride counterion was investigated by fluorescence spectroscopy. Benzyl alcohol was found to decrease the stability of the mixed micelles and lead to crystallization of amiodarone hydrochloride. The greatest amounts of crystals formed at 4℃ for 30 days in the model drug solutions with polysorbate 80 concentrations of 100.1 mg/mL and 97.9 mg/mL. A change of the polysorbate 80 concentration and avoidance the use of benzyl alcohol are recommended to improve the stability of the parenteral dosage form. These results can open new perspectives in the optimization of amiodarone intravenous formulations.

• Tuberculosis and Respiratory Diseases
• /
• 제41권1호
• /
• pp.51-57
• /
• 1994

저자들은 만성 심방성 세동환자에서 amiodarone 저용량으로 사용하던 중 폐독성이 발생된 1예를 경험하였기에 문헌고찰과 함께 이를 보고하는 바이다.

• Journal of Yeungnam Medical Science
• /
• 제11권1호
• /
• pp.186-192
• /
• 1994

저자들은 Lown grade IVa의 심실성 기외 수축으로 진단 받고, amiodarone을 약 7개월간 투여 받은 환자에서 amiodarone으로 야기된 간질성 폐질환의 1례를 경험하였기에 그 휘기성에 비추어 문헌 고찰과 함께 보고하는 바이다.

• Journal of Chest Surgery
• /
• 제35권8호
• /
• pp.594-598
• /
• 2002

아미오다론은 일반적인 항부정백 약물로 잘 치료되지 않는 상심실성 부정맥이나 심실성 부정맥의 치료에 효과적이라고 알려져 있는 요오드화된 벤조푸루란 유도체이다. 아미오다론으로 치료받은 환자들에게서, 속발되는 수술적 치료는 흔히 동반되는 과정이지만, 애석하게도 아미오다론으로 수술중과 수술후에 야기될 수 있는 합병증에 대해서 정확한 자료를 가지고 있지 못한 것이 현실이다. 일부 보고들에 따르면, 아미오다론으로 치료받던 환자들에게서 알파 교감 수용체와 베타 교감 수용체에 차단을 야기하고, 이는 수술후 혈역학적 지지에 더 많은 심근 자극과 에피네프린등의 약물을 필요로 하게 된다고 알려져 있다. 또한, 심각한 사망률과 유병율을 야기하는 아주 심각한 형태의 급성호흡부전증을 야기하게 된다고 알려져 있다. 본 교실은 승모판막치환술 후에 아미오다론으로 인하여 유발된 급성호흡부전증으로 사망한 환자를 경험하였기에 간략한 문헌고찰과 함께 보고하는 바이다.

• Journal of Yeungnam Medical Science
• /
• 제28권1호
• /
• pp.90-93
• /
• 2011

Although amiodarone is generally regarded as safe with a low incidence of associated arrhythmias, torsade de pointes (TdP) has been observed usually in the presence of predisposing factors. We report a case of amiodarone-induced TdP after long-term administration of alow dose of oral amiodarone in the absence of predisposing factors.

• Journal of Chest Surgery
• /
• 제49권3호
• /
• pp.177-184
• /
• 2016

Background: Atrial fibrillation (AF) is one of the most common complications after cardiac surgery. Several therapeutic and preventive strategies have been introduced for postoperative AF, but the treatment and prophylaxis of AF remain controversial. We aimed to compare the efficacy of intravenous amiodarone and oral propafenone in the treatment of AF after coronary artery bypass grafting (CABG). Methods: This was a randomized controlled trial performed in two hospitals in Shiraz, Iran from 2009 to 2012. We included all patients who underwent elective CABG and developed AF postoperatively. The patients were randomly assigned to receive propafenone or amiodarone. The duration of AF, the success rate of the treatment, the need for cardioversion, the frequency of repeated AF, and the need for repeating the treatment were compared. Results: The duration of the first (p=0.361), second (p=0.832), and third (p=0.298) episodes of AF, the need for cardioversion (p=0.998), and the need to repeat the first and second doses of drugs (p=0.557, 0.699) were comparable between the study groups. Repeated AF was observed in 17 patients (30.9%) in the propafenone group and 23 patients (34.3%) in the amiodarone group (p=0.704). Conclusion: Oral propafenone and intravenous amiodarone are equally effective in the treatment and conversion of recent-onset AF after CABG.

• 대한한방내과학회지
• /
• 제24권2호
• /
• pp.387-394
• /
• 2003

Amiodarone is an effective antiarrhythmic agent because of its vasodilator actions. Nowadays it is mostly used to treat patients with severe cardiomyopathy or coronary artery disease complicated by disturbances in the supraventricular or ventricular rhythm. But, some doctors are reluctant to prescribe it because of its many side effects. These include impairment of liver and thyroid fuction and, rarely, damage to the lungs. Most of all, its most serious side effect is amiodarone-induced pulmonary toxicity, which can occur in up to 10% of patients, with mortality rates as high as 50%. We recently experienced one case of the patient with the Amiodarone-induced pulmonary toxicity. The clinical manifestations of the patient was cough, painful breathing, fever, presence of rales, decreased breath sounds, and sputum. We report the change of the patient's symptoms through both western medical treatment and oriental medical treatment.

• 한국응급구조학회지
• /
• 제24권3호
• /
• pp.155-160
• /
• 2020

Torsades de pointes refers to polymorphic ventricular tachycardia (PMVT), which is caused by the suppression of potassium channels owing to genetic and electrolytic abnormalities, resulting in the extension of the QT interval. Symptoms range from spontaneous circulation recovery to fainting and sudden death. Defibrillation, magnesium correction, and the use of lidocaine as an antiarrhythmic agent are recommended as treatments for persistent torsades de pointes. Currently, only amiodarone is available in the ambulance; however, torsades de pointes does not respond efficiently to amiodarone because it suppresses potassium channels and increases the refractory period of the myocardium. Lidocaine, in contrast, reduces the relative refractory period of the myocardium caused by suppressing sodium channels; thus, it inhibits the occurrence of and treats arrhythmia. In cases where PMVT did not respond to defibrillation, the administration of lidocaine showed no difference in survival and discharge rates compared to amiodarone. Thus, ambulances must be equipped with provisions to administer lidocaine.